Indeed, IL-2 stimulated proliferating PBLs also showed reduced viability, suggesting that the concentrations required to trigger AML cytotoxicity may also affect untransformed cells, limiting their potential therapeutic use. This evidence concerns the gene IL2 and acute myeloid leukemia.